Contact
searchSearch
HMP Global

Lymphoma, Leukemia & Myeloma Network

Featured

Claire Harrison, MD
Videos
Pelabresib Plus Ruxolitinib Demonstrates Deep Clinical Responses for Patients With Myelofibrosis: MANIFEST-2 Trial
09/26/2025
Claire Harrison, MD
Claire Harrison, MD, shares results from the phase 3 MANIFEST-2 evaluating the clinical efficacy of pelabresib combined with ruxolitinib compared with ruxolitinib alone for patients with myelofibrosis naïve to JAK inhibitor therapy.
Claire Harrison, MD, shares results from the phase 3 MANIFEST-2 evaluating the clinical efficacy of pelabresib combined with ruxolitinib compared with ruxolitinib alone for patients with myelofibrosis naïve to JAK inhibitor therapy.
Claire Harrison, MD, shares...
09/26/2025
Oncology
From Oncology
Quiz
INCB057643 Therapy for R/R Myelofibrosis
09/26/2025
True or False: The small-molecular BET inhibitor INCB057643 demonstrated promising clinical activity and tolerability both as a monotherapy and combined with ruxolitinib for patients with relapsed/refractory myelofibrosis.
True or False: The small-molecular BET inhibitor INCB057643 demonstrated promising clinical activity and tolerability both as a monotherapy and combined with ruxolitinib for patients with relapsed/refractory myelofibrosis.
True or False: The...
09/26/2025
Oncology
From Oncology
Quiz
Epcoritamab Plus R-ICE for R/R DLBCL
09/26/2025
True or False: According to results from the EPCORE NHL-2 clinical trial, the addition of epcoritamab to standard R-ICE therapy demonstrated high overall and complete response rates among patients with R/R DLBCL eligible for autologous stem...
True or False: According to results from the EPCORE NHL-2 clinical trial, the addition of epcoritamab to standard R-ICE therapy demonstrated high overall and complete response rates among patients with R/R DLBCL eligible for autologous stem...
True or False: According to...
09/26/2025
Oncology
From Oncology
News
Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL
09/26/2025
Emily Estrada
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE...
09/26/2025
Oncology
From Oncology
News
PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL
09/26/2025
Emily Estrada
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large...
09/26/2025
Oncology
From Oncology
News
Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies
09/26/2025
Emily Estrada
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional...
09/26/2025
Oncology
From Oncology
News
Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology
From Oncology
Quiz
Amulirafusp Alfa Plus Lenalidomide for R/R FL
09/24/2025
True or False: According to a phase 2 trial, the combination of amulirafusp alfa and lenalidomide demonstrated encouraging early clinical activity and an acceptable safety profile among patients with R/R CD20-positive follicular lymphoma.
True or False: According to a phase 2 trial, the combination of amulirafusp alfa and lenalidomide demonstrated encouraging early clinical activity and an acceptable safety profile among patients with R/R CD20-positive follicular lymphoma.
True or False: According to a...
09/24/2025
Oncology
From Oncology
News
Belantamab Mafodotin Shows Real-World Efficacy Among Patients With Heavily Pretreated Multiple Myeloma
09/15/2025
Emily Estrada
In a real-world observational analysis, belantamab mafodotin demonstrated clinical activity for patients with heavily pretreated relapsed/refractory multiple myeloma.
In a real-world observational analysis, belantamab mafodotin demonstrated clinical activity for patients with heavily pretreated relapsed/refractory multiple myeloma.
In a real-world observational...
09/15/2025
Oncology
From Oncology
Quiz
Ruxolitinib Combined With Novel Agents for the Treatment of MF
09/12/2025
True or False: According to results from the ADORE clinical trial, ruxolitinib combined with siremadlin treatment demonstrated the least promising safety and efficacy for patients with myelofibrosis, compared with other novel agents in...
True or False: According to results from the ADORE clinical trial, ruxolitinib combined with siremadlin treatment demonstrated the least promising safety and efficacy for patients with myelofibrosis, compared with other novel agents in...
True or False: According to...
09/12/2025
Oncology
From Oncology
Quiz
Allogeneic Stem Cell Transplantation for R/R CLL
09/11/2025
True or False: For patients with high-risk or R/R chronic lymphocytic leukemia, including those previously treated with pathway inhibitors, allogeneic hematopoietic stem cell transplantation demonstrated improved outcomes.
True or False: For patients with high-risk or R/R chronic lymphocytic leukemia, including those previously treated with pathway inhibitors, allogeneic hematopoietic stem cell transplantation demonstrated improved outcomes.
True or False: For patients with...
09/11/2025
Oncology
From Oncology

Interactive Features

Quiz
INCB057643 Therapy for R/R Myelofibrosis
09/26/2025
True or False: The small-molecular BET inhibitor INCB057643 demonstrated promising clinical activity and tolerability both as a monotherapy and combined with ruxolitinib for patients with relapsed/refractory myelofibrosis.
True or False: The small-molecular BET inhibitor INCB057643 demonstrated promising clinical activity and tolerability both as a monotherapy and combined with ruxolitinib for patients with relapsed/refractory myelofibrosis.
True or False: The...
09/26/2025
Oncology
Quiz
Epcoritamab Plus R-ICE for R/R DLBCL
09/26/2025
True or False: According to results from the EPCORE NHL-2 clinical trial, the addition of epcoritamab to standard R-ICE therapy demonstrated high overall and complete response rates among patients with R/R DLBCL eligible for autologous stem...
True or False: According to results from the EPCORE NHL-2 clinical trial, the addition of epcoritamab to standard R-ICE therapy demonstrated high overall and complete response rates among patients with R/R DLBCL eligible for autologous stem...
True or False: According to...
09/26/2025
Oncology
Quiz
Amulirafusp Alfa Plus Lenalidomide for R/R FL
09/24/2025
True or False: According to a phase 2 trial, the combination of amulirafusp alfa and lenalidomide demonstrated encouraging early clinical activity and an acceptable safety profile among patients with R/R CD20-positive follicular lymphoma.
True or False: According to a phase 2 trial, the combination of amulirafusp alfa and lenalidomide demonstrated encouraging early clinical activity and an acceptable safety profile among patients with R/R CD20-positive follicular lymphoma.
True or False: According to a...
09/24/2025
Oncology
Quiz
Ruxolitinib Combined With Novel Agents for the Treatment of MF
09/12/2025
True or False: According to results from the ADORE clinical trial, ruxolitinib combined with siremadlin treatment demonstrated the least promising safety and efficacy for patients with myelofibrosis, compared with other novel agents in...
True or False: According to results from the ADORE clinical trial, ruxolitinib combined with siremadlin treatment demonstrated the least promising safety and efficacy for patients with myelofibrosis, compared with other novel agents in...
True or False: According to...
09/12/2025
Oncology
Quiz
Allogeneic Stem Cell Transplantation for R/R CLL
09/11/2025
True or False: For patients with high-risk or R/R chronic lymphocytic leukemia, including those previously treated with pathway inhibitors, allogeneic hematopoietic stem cell transplantation demonstrated improved outcomes.
True or False: For patients with high-risk or R/R chronic lymphocytic leukemia, including those previously treated with pathway inhibitors, allogeneic hematopoietic stem cell transplantation demonstrated improved outcomes.
True or False: For patients with...
09/11/2025
Oncology
Quiz
Efficacy and Safety of Tazemetostat for R/R DLBCL and FL
08/25/2025
True or False: Based on results from a meta-analysis evaluating the safety and efficacy of tazemetostat among patients with R/R FL or DLBCL, the EZH2 inhibitor demonstrated promise as a viable treatment option, demonstrating meaningful...
True or False: Based on results from a meta-analysis evaluating the safety and efficacy of tazemetostat among patients with R/R FL or DLBCL, the EZH2 inhibitor demonstrated promise as a viable treatment option, demonstrating meaningful...
True or False: Based on results...
08/25/2025
Oncology
Quiz
Venetoclax and CPX-531 for R/R AML
08/25/2025
True or False: In a phase 1b/2 trial evaluating the efficacy and safety of venetoclax plus CPX-531 for the treatment of R/R acute myeloid leukemia, the combination therapy showed promising clinical activity, especially among patients in...
True or False: In a phase 1b/2 trial evaluating the efficacy and safety of venetoclax plus CPX-531 for the treatment of R/R acute myeloid leukemia, the combination therapy showed promising clinical activity, especially among patients in...
True or False: In a phase 1b/2...
08/25/2025
Oncology
Quiz
Ziftomenib Monotherapy for R/R NPM1-Mutant AML
08/13/2025
True or False: According to results from the phase 2 KOMET-001 trial, ziftomenib demonstrated promising efficacy and safety among patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.
True or False: According to results from the phase 2 KOMET-001 trial, ziftomenib demonstrated promising efficacy and safety among patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.
True or False: According to...
08/13/2025
Oncology
Quiz
Venetoclax Plus Bortezomib and Dexamethasone Therapy for R/R MM
08/04/2025
In the phase 3 BELLINI clinical trial, patients with R/R multiple myeloma who received venetoclax combined with bortezomib and dexamethasone demonstrated what median PFS compared to treatment with a placebo?
In the phase 3 BELLINI clinical trial, patients with R/R multiple myeloma who received venetoclax combined with bortezomib and dexamethasone demonstrated what median PFS compared to treatment with a placebo?
In the phase 3 BELLINI clinical...
08/04/2025
Oncology
Quiz
Olutasidenib for R/R IDH1-Mutant AML
07/17/2025
In the post hoc analysis evaluating olutasidenib for R/R IDH1-mutant AML, patients treated earlier in the treatment sequence (after 1 to 2 prior regimens) demonstrated which overall response rate?
In the post hoc analysis evaluating olutasidenib for R/R IDH1-mutant AML, patients treated earlier in the treatment sequence (after 1 to 2 prior regimens) demonstrated which overall response rate?
In the post hoc analysis...
07/17/2025
Oncology

Insights

Claire Harrison, MD
Videos
Pelabresib Plus Ruxolitinib Demonstrates Deep Clinical Responses for Patients With Myelofibrosis: MANIFEST-2 Trial
09/26/2025
Claire Harrison, MD
Claire Harrison, MD, shares results from the phase 3 MANIFEST-2 evaluating the clinical efficacy of pelabresib combined with ruxolitinib compared with ruxolitinib alone for patients with myelofibrosis naïve to JAK inhibitor therapy.
Claire Harrison, MD, shares results from the phase 3 MANIFEST-2 evaluating the clinical efficacy of pelabresib combined with ruxolitinib compared with ruxolitinib alone for patients with myelofibrosis naïve to JAK inhibitor therapy.
Claire Harrison, MD, shares...
09/26/2025
Oncology
Jorge Cortes, MD
Videos
Latest Advancements in the Treatment of Chronic Myeloid Leukemia
09/10/2025
Jorge Cortes, MD
Jorge Cortes, MD shares recent progress in the treatment of chronic myeloid leukemia, highlighting the use of asciminib for patients including those who have not responded to other tyrosine kinase inhibitors.
Jorge Cortes, MD shares recent progress in the treatment of chronic myeloid leukemia, highlighting the use of asciminib for patients including those who have not responded to other tyrosine kinase inhibitors.
Jorge Cortes, MD shares recent...
09/10/2025
Oncology
Raajit Rampal, MD, PhD
Conference Coverage
Pacritinib Therapy May Improve Hemoglobin Responses Among Patients With Myelofibrosis
09/03/2025
Raajit Rampal, MD, PhD
Raajit Rampal, MD, PhD shares results from a real-world analysis evaluating outcomes and hemoglobin responses among patients with myelofibrosis who were treated with pacritinib.
Raajit Rampal, MD, PhD shares results from a real-world analysis evaluating outcomes and hemoglobin responses among patients with myelofibrosis who were treated with pacritinib.
Raajit Rampal, MD, PhD shares...
09/03/2025
Oncology
Amer Zeidan, MBBS, MHS
Conference Coverage
Ziftomenib Plus Standard Induction Therapy Demonstrates Meaningful Clinical Activity for Patients With AML: KOMET-007
08/25/2025
Amer Zeidan, MBBS
At the EHA 2025 Congress, Amer Zeidan, MBBS, MHS, shared results from the KOMET-007 trial which evaluated the efficacy of ziftomenib combined with standard induction therapy for patients with newly diagnosed acute myeloid leukemia.
At the EHA 2025 Congress, Amer Zeidan, MBBS, MHS, shared results from the KOMET-007 trial which evaluated the efficacy of ziftomenib combined with standard induction therapy for patients with newly diagnosed acute myeloid leukemia.
At the EHA 2025 Congress, Amer...
08/25/2025
Oncology
Amer Zeidan, MBBS, MHS
Conference Coverage
Decitabine-Cedazuridine Plus Venetoclax Therapy Shows Efficacy and Safety for Patients With Newly Diagnosed AML
08/20/2025
Amer Zeidan, MBBS
Amer Zeidan, MBBS, MHS, shares results from a phase 2 trial determining the safety and efficacy of decitabine-cedazuridine plus venetoclax for patients with newly diagnosed acute myeloid leukemia ineligible for induction chemotherapy.
Amer Zeidan, MBBS, MHS, shares results from a phase 2 trial determining the safety and efficacy of decitabine-cedazuridine plus venetoclax for patients with newly diagnosed acute myeloid leukemia ineligible for induction chemotherapy.
Amer Zeidan, MBBS, MHS, shares...
08/20/2025
Oncology
Joshua Richter, MD
Conference Coverage
Benefits of Dual Maintenance Therapy for Treating Multiple Myeloma Following Transplantation
08/20/2025
Joshua Richter, MD
At the 2025 Great Debates in Hematologic Malignancies meeting, Joshua Richter, MD, argues for the benefits of dual maintenance therapy following autologous stem cell transplantation to improve responses among patients with multiple myeloma.
At the 2025 Great Debates in Hematologic Malignancies meeting, Joshua Richter, MD, argues for the benefits of dual maintenance therapy following autologous stem cell transplantation to improve responses among patients with multiple myeloma.
At the 2025 Great Debates in...
08/20/2025
Oncology
Noa Biran, MD
Conference Coverage
Evaluating the Role of Dual Maintenance Therapy for Patients With MM Following Transplant
08/20/2025
Noa Biran, MD
Noa Biran, MD participated in a debate on the role of dual maintenance therapy following transplant for patients with multiple myeloma at the 2025 Great Debates in Hematologic Malignancies meeting.
Noa Biran, MD participated in a debate on the role of dual maintenance therapy following transplant for patients with multiple myeloma at the 2025 Great Debates in Hematologic Malignancies meeting.
Noa Biran, MD participated in a...
08/20/2025
Oncology
Faith Davies, MD
Conference Coverage
Determining When Treatment for Patients With High-Risk Smoldering MM is Appropriate
08/06/2025
Faith E. Davies, MD
At the 2025 Great Debates in Hematologic Malignancies meeting, Faith Davies, MD, participated in a debate on the benefits of treating patients with high-risk smoldering multiple myeloma.
At the 2025 Great Debates in Hematologic Malignancies meeting, Faith Davies, MD, participated in a debate on the benefits of treating patients with high-risk smoldering multiple myeloma.
At the 2025 Great Debates in...
08/06/2025
Oncology
Peter Voorhees, MD
Conference Coverage
Strategy for Treatment of High-Risk Smoldering Myeloma Prior to Disease Progression
08/06/2025
Peter Voorhees, MD
At the 2025 Great Debates in Hematologic Malignancies meeting, Peter Voorhees, MD, discusses strategies for treating patients with high-risk smoldering multiple myeloma to prevent or slow disease progression, citing findings from the phase 3...
At the 2025 Great Debates in Hematologic Malignancies meeting, Peter Voorhees, MD, discusses strategies for treating patients with high-risk smoldering multiple myeloma to prevent or slow disease progression, citing findings from the phase 3...
At the 2025 Great Debates in...
08/06/2025
Oncology
Naval Daver, MD
Conference Coverage
Challenges of Applying MRD Decision-Making to Determine Transplant Among Patients With AML
08/05/2025
Naval G. Daver
At the 2025 Great Debates in Hematologic Malignancies meeting, Naval Daver, MD, debates against minimal residual disease negativity as the predominate determining factor for transplant eligibility among patients with acute myeloid leukemia.
At the 2025 Great Debates in Hematologic Malignancies meeting, Naval Daver, MD, debates against minimal residual disease negativity as the predominate determining factor for transplant eligibility among patients with acute myeloid leukemia.
At the 2025 Great Debates in...
08/05/2025
Oncology

Meeting Materials

In the News

News
Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL
09/26/2025
Emily Estrada
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE...
09/26/2025
Oncology
News
PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL
09/26/2025
Emily Estrada
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large...
09/26/2025
Oncology
News
Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies
09/26/2025
Emily Estrada
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional...
09/26/2025
Oncology
News
Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology
News
Belantamab Mafodotin Shows Real-World Efficacy Among Patients With Heavily Pretreated Multiple Myeloma
09/15/2025
Emily Estrada
In a real-world observational analysis, belantamab mafodotin demonstrated clinical activity for patients with heavily pretreated relapsed/refractory multiple myeloma.
In a real-world observational analysis, belantamab mafodotin demonstrated clinical activity for patients with heavily pretreated relapsed/refractory multiple myeloma.
In a real-world observational...
09/15/2025
Oncology
News
Ibrutinib Plus Chemoimmunotherapy Approved by European Commission for Patients With Previously Untreated MCL: TRIANGLE Trial
07/24/2025
Emily Estrada
The European Commission has approved ibrutinib combined with chemoimmunotherapy for the treatment of mantle cell lymphoma based on results from the phase 3 TRIANGLE clinical trial which demonstrated superior survival outcomes compared with...
The European Commission has approved ibrutinib combined with chemoimmunotherapy for the treatment of mantle cell lymphoma based on results from the phase 3 TRIANGLE clinical trial which demonstrated superior survival outcomes compared with...
The European Commission has...
07/24/2025
Oncology
News
AQUILA Phase 3 Trial Leads to European Commission Approval of Daratumumab for Smoldering Multiple Myeloma
07/24/2025
Emily Estrada
For patients with high-risk smoldering multiple myeloma, fixed-duration daratumumab has been approved by the European Commission based on results from the AQUILA phase 3 clinical trial.
For patients with high-risk smoldering multiple myeloma, fixed-duration daratumumab has been approved by the European Commission based on results from the AQUILA phase 3 clinical trial.
For patients with high-risk...
07/24/2025
Oncology
News
Patients With Acute Myeloid Leukemia and Concurrent DNMT3A and TET2 Mutations Demonstrate Lower Survival Outcomes
07/17/2025
Emily Estrada
Among elderly patients with AML, DNMT3A and TET2 mutations are associated with worse survival outcomes, while IDH1/IDH2 mutations are associated with improved survival, though these mutations were not found to significantly influence choice...
Among elderly patients with AML, DNMT3A and TET2 mutations are associated with worse survival outcomes, while IDH1/IDH2 mutations are associated with improved survival, though these mutations were not found to significantly influence choice...
Among elderly patients with AML,...
07/17/2025
Oncology
News
Pomalidomide-Based Regimen Shows Improved Overall Response Rate and Progression-Free Survival for Patients With MM in First Relapse
07/17/2025
Emily Estrada
A regimen of bortezomib and dexamethasone plus pomalidomide demonstrated superior survival outcomes and responses among patients with first-relapsed multiple myeloma, compared with bortezomib and dexamethasone alone.
A regimen of bortezomib and dexamethasone plus pomalidomide demonstrated superior survival outcomes and responses among patients with first-relapsed multiple myeloma, compared with bortezomib and dexamethasone alone.
A regimen of bortezomib and...
07/17/2025
Oncology
Conference Coverage
BET Inhibitor INCB057643 Shows Promising Efficacy for Treatment of Relapsed/Refractory Myelofibrosis
07/14/2025
Emily Estrada
The small-molecular BET inhibitor, INCB057643, demonstrated clinical activity and manageable safety among patients with relapsed/refractory myelofibrosis.
The small-molecular BET inhibitor, INCB057643, demonstrated clinical activity and manageable safety among patients with relapsed/refractory myelofibrosis.
The small-molecular BET...
07/14/2025
Oncology

Latest Podcasts

Podcasts
Dr Leonard Shares Highlights to Expect at the 2020 Lymphoma, Leukemia & Myeloma Congress
10/19/2020
John Leonard, MD, discusses what to expect at the virtual 2020 Lymphoma, Leukemia & Myeloma Congress taking place October 21-24, 2020.
John Leonard, MD, discusses what to expect at the virtual 2020 Lymphoma, Leukemia & Myeloma Congress taking place October 21-24, 2020.
John Leonard, MD, discusses what...
10/19/2020
Oncology
What to Expect at the Non-Malignant Hematology Workshop at Lymphoma, Leukemia & Myeloma Congress
Podcasts
What to Expect at the Non-Malignant Hematology Workshop at Lymphoma, Leukemia & Myeloma Congress
08/24/2020
James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.
James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.
James B. Bussel, MD, gives an...
08/24/2020
Oncology
Podcasts
Seattle Children's Hospital Leukemia Program Offers Multidisciplinary Care to Underserved Population
06/19/2018
Todd Cooper, DO, discusses a new program launched at The Seattle Children's Hospital for patients with high-risk leukemia.
Todd Cooper, DO, discusses a new program launched at The Seattle Children's Hospital for patients with high-risk leukemia.
Todd Cooper, DO, discusses a new...
06/19/2018
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use